Novo Nordisk (NOVOB.DK) shares are losing 20% after the pharmaceutical giant, known for its obesity drugs Ozempic and Wegova, released disappointing clinical trial data for its experimental obesity drug CagriSema. Patients treated with Novo's next-generation weight-loss drug CagriSema lost an average of 22.7% of their weight after 68 weeks, falling short of the 25% goal the drugmaker expected. About 40% of patients lost 25% or more of their body weight.

The company's shares are trading at their lowest since August 2023. Source: xStation
Netflix disappoints Wall Street 🚩 Stock drops 9% after disappointing outlook
Morninga Wrap: Wall Street Under Pressure. AI Loses Momentum, Netflix Disappoints, and the Persian Gulf Erupts
Daily Summary: 📉 A Red Day Across Markets. AI Sector Weighs on Wall Street, Precious Metals Under Pressure
Stock of the Week: ASML – The Machines Driving the Future of Semiconductors